Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 5, 2010, Pages 2376-2383

  Anuurad, Erdembileg ^a   Ozturk, Zeynep ^a,c   Enkhmaa, Byambaa ^a   Pearson, Thomas A ^d   Berglund, Lars ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c ISTANBUL UNIVERSITY   (Turkey)

^d UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AFRICAN AMERICAN; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONFOUNDING VARIABLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ETHNIC DIFFERENCE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; OUTCOME ASSESSMENT; POPULATION RISK; PREDICTION; PRIORITY JOURNAL; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; INSULIN RESISTANCE; NEGRO; PREDICTION AND FORECASTING; RADIOGRAPHY; REGRESSION ANALYSIS; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AFRICAN CONTINENTAL ANCESTRY GROUP; CORONARY ANGIOGRAPHY; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INSULIN RESISTANCE; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RISK FACTORS;

EID: 77952758917     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2498     Document Type: Article

References (34)

1. Ross R 1999 Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126
2. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD 2000 Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343:1148-1155
3. Caslake MJ, Packard CJ 2003 Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 14:347-352
4. Koenig W, Khuseyinova N, Löwel H, Trischler G, Meisinger C 2004 Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110:1903-1908
5. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR 2004 Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109:837-842
6. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM 2001 A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 38:1302-1306
7. Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, Lerman A 2007 Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 115:2715-2721
8. Blankenberg S, Stengel D, Rupprecht HJ, Bickel C, Meyer J, Cambien F, Tiret L, Ninio E 2003 Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res 44:1381-1386
9. Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M, Oldgren J, Rossi GP, Maiolino G, Cesari M, Lenzini L, James SK, Rimm E, Collins R, Anderson J, Koenig W, Brenner H, Rothenbacher D, Berglund G, Persson M, Berger P, Brilakis E, McConnell JP, Koenig W, Sacco R, et al. 2007 Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil 14:3-11
10. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F 2007 Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 82:159-165 (Pubitemid 46198473)
11. Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, Lerman A, McConnell JP, Weintraub HS 2008 Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 101:51F-57F
12. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon 3rd RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith Jr SC, Taubert K, Tracy RP, Vinicor F 2003 Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511
13. 2002 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421
14. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937-952 (Pubitemid 39208455)
15. Paultre F, Pearson TA, Weil HF, Tuck CH, Myerson M, Rubin J, Francis CK, Marx HF, Philbin EF, Reed RG, Berglund L 2000 High levels of Lp (a) with a small apo (a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 20:2619-2624
16. Anuurad E, Rubin J, Lu G, Pearson TA, Holleran S, Ramakrishnan R, Berglund L 2006 Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol. J Lipid Res 47:2475-2481
17. McGowan MW, Artiss JD, Strandbergh DR, Zak B 1983 A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 29:538-542 (Pubitemid 13160770)
18. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC 1974 Enzymatic determination of total serum cholesterol. Clin Chem 20:470-475
19. Warnick GR, Benderson J, Albers JJ 1982 Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 28:1379-1388
20. Maciejko JJ, Levinson SS, Markyvech L, Smith MP, Blevins RD 1987 New assay of apolipoproteins A-I and B by rate nephelometry evaluated. Clin Chem 33:2065-2069
21. Adler AI, Levy JC, Matthews DR, Stratton IM, Hines G, Holman RR 2005 Insulin sensitivity at diagnosis of type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67). Diabet Med 22:306-311
22. Dada N, Kim NW, Wolfert RL 2002 Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn 2:17-22
23. Koenig W, Twardella D, Brenner H, Rothenbacher D 2006 Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 26:1586-1593
24. Kosaka T, Yamaguchi M, Soda Y, Kishimoto T, Tago A, Toyosato M, Mizuno K 2000 Spectrophotometric assay forserumplatelet-activating factor acetylhydrolase activity. Clin Chim Acta 296:151-161
25. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD 2007 Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 27:2236-2243
26. Miller M, Mead LA, Kwiterovich Jr PO, Pearson TA 1990 Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. Am J Cardiol 65:1-5
27. Iribarren C, Gross MD, Darbinian JA, Jacobs Jr DR, Sidney S, Loria CM 2005 Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 25:216-221
28. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC 2005 Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111:570-575 (Pubitemid 40216483)
29. Winkler K, Hoffmann MM, Winkelmann BR, Friedrich I, Schäfer G, Seelhorst U, Wellnitz B, Wieland H, Boehm BO, März W 2007 Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem 53:1440-1447
30. Furberg CD, Nelson JJ, Solomon C, Cushman M, Jenny NS, Psaty BM 2008 Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study. J Am Geriatr Soc 56:792-799
31. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, Witztum JL, Wiedermann CJ, Xu Q, Kiechl S 2009 Lipoproteinassociated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J 30:107-115
32. Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, Murphy SA, de Lemos JA 2008 Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis 199:110-115
33. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M 2000 Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 150:209-216
34. El-Saed A, Sekikawa A, Zaky RW, Kadowaki T, Takamiya T, Okamura T, Edmundowicz D, Kita Y, Kuller LH, Ueshima H 2007 Association of lipoprotein-associated phospholipase A2 with coronary calcification among American and Japanese men. J Epidemiol 17:179-185